i significant interest opioids specifically opioid use disorders addiction opioids seen opioid epidemic country largely due na approach chronic pain exposing people unnecessarily risk addiction one level failure regulators adopted idea chronic noncancer pain best treated mass basis opioids another level failure american culture americans focused abusable medications always recent phenomenon reason addictive drugs regulated first place widely abused could purchased counter pharmacy advocates legalizing drugs almost universally ignore fact common find people hoarding opioid prescriptions giving neighbors taking indications pain like insomnia depression anxiety cultural level opioids generally regarded magical pills cure whatever ails pill physicians blameless process around turn th century physicians maintaining large numbers people addiction part medical practice turn th century physicians advocated pain fifth vital sign widespread practice recording patient pain rating routine clinic visits vital signs cases rating mischaracterized objective measure like vital signs physician told pain rating scale knows little objectivity involved opioid epidemic often viewed problem physician education cognitive deficiency i doubt problem every physician knows basics prescribing opioids time leave medical school i recall working clinic chronic pain patients i medical student clinic prescribed hundreds opioid prescriptions per month i also recall none patients ever asked addiction still wanted take medications even though pain never seemed improve problem also led significant insights real function food drug administration fda fda web site three paragraphs first paragraph highlights i always thought main function agency fda responsible protecting public health assuring safety efficacy security human veterinary drugs biological products medical devices nation food supply cosmetics products emit radiation seems like straightforward definition practice complicated best example i think illustrate fda approval sustained release high dose hydrocodone product norco fda scientific committee overwhelmingly recommended approving product midst opioid epidemic overruled product approved based solely manufacturer meeting regulatory requirements despite concern getting medications market fast enough seems like obstacle opioid preparations basically old medications repacked new form financial considerations field significant several years ago speculation successful abuse deterrent opioid formulation would billion dollar year drug manufacturer highlighted number recent approvals drugs noted table current market abuse deterrent opioids estimated billion global pain market estimated worth billion growing rate annually table apparent basically patent extension market main ingredients medications generic opioids inexpensive putting special formulation combining opioid antagonists naltrexone naloxone manufacturers claim producing medication less likely abused whether ultimately happens anybody guess i tried pull one notable prodrug use web sites seen compounds far suggestion defeat abuse deterrence historical precedents abusable drugs generally follow predictable course oral use smoking insufflation snorting intravenous use breaking chain events one strategy may lead less severe drug use fact remains original oral formulation still potent medication lead addiction original case point reformulation oxycontin original capsule could breached contents snorted smoked injected reformulation put oxycodone hydrogel making less available snorting smoking injecting detailed package insert still says formulation original formulation place user risk addiction learned proliferation abuse deterrent formulations strong incentive terms market size low production costs medications table inexpensive generics reformulated inexpensive antagonist different pill matrix main safeguard fda terms total number medications market fda potential decrease incidence opioid use disorders evidence strategy approving medications objections scientific committee cases discuss post marketing surveillance measure whether abuse deterrent medication working neither strategies would seem likely me well known reports signifiant medication related events probably low relative actual incidence events i previously advocated pharmacosurveillance data mining solution would produce results expected complications opioid dependence unintentional overdoses fda current approach seems education physicians solve problem problem physician education formulations opioids continue propagate needs awareness fda attempting contain number new opioid products released preventive approach necessary likely save lives waiting people report complications waiting drug enforcement agency make arrests also time consider done level american culture focusing basic misperceptions result overvaluation opioids idea opioids alleviate chronic pain best treatment chronic pain everyone take safely primary among also needs better understanding opioid use disorders recent stories popular press make seem like addictions easy problems get make decision stop people able tell old story returning vietnam vets easy stop using heroin people seen acute care settings treated drug overdoses many people say knew using lot drug thinking suicide care lived died i wanted get high powerful incentive defeating abuse deterrent pills george dawson md dfapa supplementary new drug application nda formal application fda sponsor usually pharmaceutical company proposes new drug approved sale marketing united states detailed information fda web site follow link